derivatives (7a–7d, 10a–10d and 13a–13f) have been synthesised and assessed for their potential EGFR and VEGFR-2 inhibitory activities. Compounds 10b and 10d exerted potent and selective inhibitory activity towards the two receptor tyrosine kinases; EGFR (IC50 = 40.7 ± 1.0 and 32.5 ± 2.2 nM, respectively) and VEGFR-2 (IC50 = 78.4 ± 1.5 and 43.0 ± 2.4 nM, respectively). The best anti-proliferative activity
摘要 已合成新系列
噻唑基-
吡唑啉衍
生物(7a-7d、10a-10d和13a-13f )并评估其潜在的
EGFR 和 V
EGFR-2 抑制活性。化合物10b和10d对两种受体
酪氨酸激酶具有强效和选择性抑制活性;
EGFR(IC 50 = 40.7 ± 1.0 和 32.5 ± 2.2 nM,分别)和 V
EGFR-2(IC 50 = 78.4 ± 1.5 和 43.0 ± 2.4 nM,分别)。对非小肺癌细胞 (NSCLC) 观察到所检查的
噻唑基-
吡唑啉的最佳抗增殖活性。化合物10b和10d对 A549(IC50 = 4.2 和 2.9 µM,分别)和 H441
细胞系(IC 50 = 4.8 和 3.8 µM,分别)。此外,我们的结果表明,10b和10d对
EGFR 突变的 NSCLC
细胞系(NCI-H1650 和 NCI-H1975 细胞)比
吉非替尼更有效。最后,化合物10b和10d诱导 G2/M